CT 2106

Drug Profile

CT 2106

Alternative Names: PG camptothecin; PG-CPT; Polyglutamate camptothecin

Latest Information Update: 21 Jul 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cell Therapeutics
  • Class Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 06 Jun 2006 Data presented at the 42nd Annual Meeting of the American Society for Clinical Oncology (ASCO-2006) have been added to the adverse events and pharmacokinetics sections
  • 14 Dec 2004 Phase-II clinical trials in Ovarian cancer in Europe (IV)
  • 22 Apr 2004 Phase-I/II clinical trials in Colorectal cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top